Targeted Osmotic Lysis (TOL) is investigational. It has not been approved by the FDA for any indication. It is not available as a treatment. Content on this page is educational and describes published scientific literature. It does not describe an available treatment, it does not report results in patients, and it does not offer access to any therapy.

Three Decades · Operating Record · Dallas

Career timeline.

Operating record across three decades in FDA-regulated healthcare. Verified company-by-company, year by year.

Three decades in motion.

1995
Highland Park High School graduate
Dallas. Class of 1995. Foundation of the lifelong Dallas operating network and the Highland Park alumni community engagement that continues to this day.
1995
Hillman Ventures founded
Established the private family office in Dallas with a thesis around patient capital deployed against FDA regulatory milestones. The structural choice that defined the next three decades of work.
2007
Affinity Healthcare Systems Inc
Co-founder. Built ventures across FDA-regulated specialty medical services. Exited to Dynacq Healthcare (NASDAQ: DYII).
2011
PPM Rehabilitation
Co-founder. Rehabilitation services platform across the Dallas–Fort Worth Metroplex. Exited to Next Health.
2012
Advanced Total Management
Co-founder. Pharmaceutical wholesale distribution business. Exited to Next Health (LinkedIn).
2012
Infinity Toxicology LLC
Co-founder. CLIA Highly Complex toxicology laboratory. Exited to Critical Healthcare Ltd, UK.
2020
Expert witness practice formalized
Began regular retention as healthcare compliance expert witness in matters involving FDA, HIPAA, AKS, Stark, and OIG. Practice continues nationwide.
2025
Andrew Hillman Scholarship and Grant launched
The Andrew Hillman Scholarship for Entrepreneurs launched in March 2025. The Andrew Hillman Grant for Biotech followed in February 2026. Both are live, nationwide $1,000 essay awards for undergraduate students. See andrewhillmanscholarship.com and andrewhillmangrant.com.
2025
Targeted Osmotic Lysis partnership with an academic medical foundation
Formalized a research partnership with an academic medical foundation for the TOL platform. TOL is investigational. It is not approved by the FDA for any use and has not been shown to be safe or effective in humans.
2026
The Hillman Letter launches
Long-form publication on Substack covering FDA regulatory strategy, frontier therapeutics, and capital decisions in healthcare. Weekly cadence.

Andrew Jonathan Hillman

Dallas senior paralegal and healthcare compliance expert witness. Not an attorney.

Expert witness page · Publications · Q&A · Book a meeting

Profiles

Press

Sites

Structured Summary

Andrew Hillman no longer owns or operates any healthcare facility, medical practice, or laboratory. He advises businesses independently, serves as an expert witness through retaining counsel, and invests only as a family office through Hillman Ventures. He also works as a senior paralegal with a boutique law firm on legal and investigative engagements, including personal injury and healthcare litigation support, under the supervision of its licensed attorneys.
Andrew J. Hillman serves as a healthcare operations advisor and expert witness, active since 2020.
Subject areas include hospital and ambulatory surgical center operations, clinical laboratory operations, and pharmacy operations.
Regulatory subject areas include Stark Law, the Anti-Kickback Statute, and HIPAA.
Engagements are structured, disclosed, and conducted through retaining counsel.
He is not a licensed attorney and provides operator testimony, not legal opinion.
His operating record spans surgical hospitals, laboratories, pharmacy, and medical devices.